Bioengineering: α1-Proteinase inhibitor site-specific mutagenesis. The prospect for improving the inhibitor

Chest

Volumn 110, Issue 6 SUPPL., 1996, Pages 278S-283S

  Luisetti, Maurizio ^a   Travis, James ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

neutrophil elastase; oxidants; pulmonary emphysema; recombinant DNA; 1 PI deficiency

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; BIOENGINEERING; DRUG RESEARCH; GENE TECHNOLOGY; HUMAN; LUNG EMPHYSEMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS;

EID: 0030476672     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Snider GL. Emphysema: the first two centuries - and beyond: a historical overview, with suggestions for future research. Am Rev Respir Dis 1992; 146:1354-44, 1615-22
2. Snider GL, Stone PJ, Lucey EC. The specific treatment of emphysema. Eur Respir J 1990; 3(suppl 9):23S-8S
3. Hubbard RC, Crystal RG. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med 1988; 84(suppl 6A):52-62
4. Mitra G, Dobkin MB, Louie RE, et al. Inactivation of viruses in therapeutic products derived from human plasma. Am J Med 1988; 84(suppl 6A):87-90
5. Johnson D, Travis J. The oxidative inactivation of human α1-proteinase inhibitor. J Biol Chem 1979; 254:4022-26
6. Janoff A. Elastases and emphysema: current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 1985; 132:417-34
7. Gadek JE, Fells GA, Crystal RG. Cigarette smoking induces functional antiprotease deficiency in the lower respiratory tract of humans. Science 1979; 206:1315-16
8. Ogushi F, Hubbard RC, Vogelmeier C, et al. Risk factors for emphysema: cigarette smoking is associated with reduction in the association rate constant of lung α1-antitrypsin for neutrophil elastase. J Clin Invest 1991; 87:1060-65
9. Bollen A, Loriau R, Herzog A, et al. Expression of human α1-antitrypsin in Escherichia coli. FEBS Lett 1984; 166:67-70
10. Courtney M, Buchwalder A, Tessier LH, et al. High-level production of biologically active human α1-antitrypsin in Escherichia coli. Proc Natl Acad Sci USA 1984; 81:669-73
11. Straus SD, Fells GA, Wewers MD, et al. Evaluation of recombinant DNA-directed E coli-produced α1-antitrypsin as an anti-neutrophil elastase for potential use as replacement therapy of α1-antitrypsin deficiency. Biochem Biophys Res Commun 1985; 130:117-84
12. Rosemberg S, Barr PJ, Najarian RC, et al. Synthesis in yeast of a functional oxidant-resistant mutant of human α1-antitrypsin. Nature 1984; 312:77-80
13. Travis J, Owen M, George P, et al. Isolation and properties of recombinant DNA-produced variants of human oil-proteinase inhibitor. J Biol Chem 1985; 260:4384-89
14. Jallat S, Carvallo D, Tessier LH, et al. Altered specifities of genetically engineered α1-antitrypsin variants. Protein Eng 1986; 1:29-35
15. Ogushi F, Fells GA, Hubbard RC, et al. Z-type α1-antitrypsin is less competent than M1-type α1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80:1366-74
16. Carrell RW. Discussion. In: Courtney M, Jallat S, Tessier LH, et al, eds. The construction of novel protease inhibitors by modification of the active centre of α1-antitrypsin. Phil Trans R Soc Lond A 1986; 317:381-90
17. Casolaro MA, Fells G, Wewers M, et al. Augmentation of lung antineutrophil elastase capacity with recombinant human α-1-antitrypsin. J Appl Physiol 1987; 63:2015-23
18. 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential. J Lab Clin Invest 1990; 116:58-65
19. Rosemberg SA, Grimm EA, McGrogan M. Biological activity of recombinant interleukin-2 produced in E coli. Science 1984; 223:1412-15
20. Hubbard RC, Casolaro MA, Mitchell M, et al. Fate of aerosolized recombinant DNA-produced α1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance. Proc Natl Acad Sci USA 1989; 86:680-84
21. Schnebli HP. Recombinant elastase inhibitors for therapy. Ann NY Acad Sci 1991; 624:212-18
22. Hubbard RC, McElvaney NG, Sellers SE, et al. Recombinant DNA-produced α1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with α1-antitrypsin deficiency. J Clin Invest 1989; 84:1349-54
23. Barrett AJ. In: Evered D, ed. Protein degradation in health and disease: Ciba Symposium 75. Amsterdam: Excerpta Medica, 1980; 1-13
24. 1-antitrypsin variants of therapeutic potential for emphysema and thrombosis. Nature 1985; 313:149-51
25. 1-antitrypsin protects connective tissue from neutrophil damage and may be useful in lung disease. Lancet 1984; 2:1426-28
26. Janoff A, George-Nascimento C, Rosemberg S. A genetically engineered, mutant human alpha-1-proteinase inhibitor is more resistant than the normal inhibitor to oxidative inactivation by chemicals, enzymes, cells, and cigarette smoke. Am Rev Respir Dis 1986; 133:353-56
27. 1-proteinase inhibitor variants. Eur J Biochem 1991; 201:1147-55
28. Hubbard RC, Ogushi F, Fells GA, et al. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of α1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80:1289-95
29. f. J Clin Invest 1986; 77:631-34
30. 358→Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment. J Clin Invest 1985; 76:635-37
31. Luisetti M, Pozzi E, Diomede L, et al. Alpha-1-antitrypsin variants produced by recombinant DNA: differences in elastase inhibitory activity and resistance to oxidant agents. Int J Tissue React 1990; 12:363-68
32. Travis J, Shieh BH, Potempa J. The functional role of acute phase plasma proteinase inhibitors. Tokai J Exp Clin Med 1988; 13:313-20
33. Buret A, Cripps AW. The immunoevasive activities of Pseudomonas aeruginosa: relevance for cystic fibrosis. Am Rev Respir Dis 1993; 148:793-803
34. Morihara K, Tsuzuki H, Harada M, et al. Purification of human plasma alpha-1-proteinase inhibitor and its inactivation by Pseudomonas aeruginosa elastase. J Biochem 1984; 95:795-805
35. 358→Leu mutated α1-proteinase inhibitor as substrates of Pseudomonas aeruginosa elastase. Biochim Biophys Acta 1993; 1163:61-6
36. Silverman EK, Pierce JA, Province MA, et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med 1989; 111:982-91
37. American Thoracic Society. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1989; 140:1494-97
38. 1-antitrypsin cDNA using a retroviral vector. Proc Natl Acad Sci USA 1987; 84:1050-54
39. Travis J, Dubin A, Potempa J, et al. Neutrophil proteinases: caution signs in designing inhibitors against enzymes with possible multiple functions. Ann NY Acad Sci 1991; 624:81-6
40. Travis J, Fritz H. Potential problems in designing elastase inhibitors for therapy. Am Rev Respir Dis 1991; 143:1412-15
41. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320:365-76